Skip to content

Real-world analysis finds similar efficacy for 2nd-line axi-cel, liso-cel in R/R LBCL
Brazil regulatory agency approves tafasitamab combo in R/R follicular lymphoma
Quizartinib similar to placebo in impact on AML patient-reported outcomes, QoL
Researchers find concomitant MM and CLL are clonally unrelated
FDA approves nivolumab in combination with AVD in cHL

Join SOHO

Follow Us :

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

About Us

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

Join SOHO

Categories

Amy DeZern, MD, MHS

Cellular Therapy

Amy DeZern, MD, MHS

Leukemia

Amy DeZern, MD, MHS

Lymphoma

Amy DeZern, MD, MHS

Multiple Myeloma

Amy DeZern, MD, MHS

Myelodysplastic Syndromes

Amy DeZern, MD, MHS

Myeloproliferative Neoplasms

Contact Info

[email protected] 1.281.364.7387

Follow Us

March 30, 2026

Insider Podcast
Society Updates
Resources
Hem/Onc Library
- Current Issue
  - Past Issues
- Cellular Therapy
- Leukemia
  - ALL
  - AML
  - CLL
  - CML
- Lymphoma
  - ABCL
  - IBCL
  - MCL
  - TCL
- MDS
- MPN
- Multiple Myeloma
Community Oncology
- Past Sessions
Meeting News
Multimedia
- Roundtable Discussions
- Video Interviews
Subscribe

SOHO Insider Amy DeZern, MD, MHS

Amy DeZern, MD, MHS

by SOHO Insider Editors
October 16, 2024
0 Comments
Less than a minute
561 Views
1 year ago

Share This Post:

Facebook Twitter Pinterest Whatsapp Cloud StumbleUpon Print Share via Email

Related Post

Lymphoma, Aggressive B-Cell Lymphomas

Real-world analysis finds similar efficacy for 2nd-line axi-cel, liso-cel

March 26, 2026

FDA Green light

Lymphoma, Indolent B-Cell Lymphomas, News

Brazil regulatory agency approves tafasitamab combo in R/R follicular

March 25, 2026

Leukemia, Acute Myeloid Leukemia

Quizartinib similar to placebo in impact on AML patient-reported

March 24, 2026

blood smear

Leukemia, Chronic Lymphocytic Leukemia, Multiple Myeloma

Researchers find concomitant MM and CLL are clonally unrelated

March 23, 2026

FDA

Lymphoma, Aggressive B-Cell Lymphomas

FDA approves nivolumab in combination with AVD in cHL

March 20, 2026

Nirav shah

Cellular Therapy, Lymphoma, Aggressive B-Cell Lymphomas, Meetings / Conferences, 2025 Tandem Meetings, News

Interim phase 2 analysis shows zamto-cel activity in DLBCL

March 19, 2026

Top Categories

Cellular Therapy

61

Leukemia

98

Lymphoma

106

Multiple Myeloma

83

Myelodysplastic Syndromes

32

Myeloproliferative Neoplasms

20

POPULAR NEWS

The Society of Hematologic Oncology (SOHO) was established as a non-profit corporation in 2012 with aims to promote worldwide research, education, prevention, clinical studies and optimal patient care in all aspects of hematologic malignancies and related disorders.

About

About Us / Editorial Board

Advertising

Contact Us

Support SOHO

Categories

Amy DeZern, MD, MHS

Cellular Therapy

Amy DeZern, MD, MHS

Leukemia

Amy DeZern, MD, MHS

Lymphoma

Amy DeZern, MD, MHS

Multiple Myeloma

Amy DeZern, MD, MHS

Myelodysplastic Syndromes

Amy DeZern, MD, MHS

Myeloproliferative Neoplasms

Subscribe

Recent Posts

Real-world analysis finds similar efficacy for 2nd-line axi-cel, liso-cel in R/R LBCL

FDA Green light

Brazil regulatory agency approves tafasitamab combo in R/R follicular lymphoma

Quizartinib similar to placebo in impact on AML patient-reported outcomes, QoL

Copyright © 2026 Society of Hematologic Oncology, All rights reserved.